| Autor: |
Miller CR; Department of Pathology, Division of Neuropathology and O'Neal Comprehensive Cancer Center, and., Hjelmeland AB; Department of Cell, Developmental, and Integrative Biology and O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama, USA. |
| Jazyk: |
angličtina |
| Zdroj: |
The Journal of clinical investigation [J Clin Invest] 2023 Nov 15; Vol. 133 (22). Date of Electronic Publication: 2023 Nov 15. |
| DOI: |
10.1172/JCI175127 |
| Abstrakt: |
Glioblastoma (GBM) tumor-associated macrophages (TAMs) provide a major immune cell population contributing to growth and immunosuppression via the production of proinflammatory factors, including IL-1. In this issue of the JCI, Chen, Giotti, and colleagues investigated loss of ll1b in the immune tumor microenvironment (TME) in GBM models driven by PDGFB expression and Nf1 knockdown. Survival was only improved in PDGFB-driven GBM models, suggesting that tumor cell genotype influenced the immune TME. IL-1β in the TME increased PDGFB-driven GBM growth by increasing tumor-derived NF-κB, expression of monocyte chemoattractants, and increased infiltration of bone marrow-derived myeloid cells (BMDMs). In contrast, no requirement for IL-1β was evident in Nf1-silenced tumors due to high basal levels of NF-κB and monocyte chemoattractants and increased infiltration of BMDM and TAMs. Notably, treatment of mice bearing PDGFB-driven GBM with anti-IL-1β or an IL1R1 antagonist extended survival. These findings suggest that effective clinical immunotherapy may require differential targeting strategies. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
